Top Net Payout Yield Stocks To Watch Right Now

Top Net Payout Yield Stocks To Watch Right Now: Titan Pharmaceuticals Inc (TTNP)

Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson's disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson's disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.

Probuphine

Probuphine is the first product to utilize the Company's ProNeura long-term d rug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.

Iloperidone

Iloperidone was evaluated in a Phase III program comp! rising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.

Spheramine

Spheramine is a cell-based therapeutic that utilizes the Company's cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with h uman retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson's disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson's disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson's disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson's disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.

Bayer Schering, the Company's corporate partner for worldwide development and commercialization of Spheramine, i! s funding! the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide develop ment, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.

Advisors' Opinion:

• [By CRWE]

  Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).

  Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine®. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-net-payout-yield-stocks-to-watch-right-now-2.html

Hot Asian Stocks To Watch For 2014

European stocks dropped, following a two-day gain, as Remy Cointreau SA (RCO) and Pernod Ricard SA dragged food-and-beverage makers lower. U.S. index futures and Asian shares were little changed.

Remy sank the most since January 2009 after forecasting that annual profit will decline by at least 10 percent. Repsol SA advanced 4 percent after the governments of Spain and Argentina reached a preliminary agreement to compensate the Madrid-based oil company for its stake in YPF SA. Algeta ASA rallied the most in more than two years after saying that Bayer AG has started talks to buy the Norwegian company.

The Stoxx Europe 600 Index slipped 0.3 percent to 323.2 at 11:20 a.m. London. The equity benchmark has surged 16 percent this year as central banks around the world pledged to leave interest rates near record lows for a prolonged period. Standard & Poor�� 500 Index futures lost less than 0.1 percent today. The MSCI Asia Pacific Index declined 0.1 percent.

�� small consolidation is taking place on the back of a few disappointing earnings reports in the beverage sector,�� Ion-Marc Valahu, a co-founder and fund manager at Clairinvest in Geneva, wrote in an e-mail. ��o far it only looks like a short-term pull back.��

Best Regional Bank Companies To Buy For 2015: Cardiome Pharma Corporation(CRME)

Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. t o develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By John Udovich]

  The biotech sector along with small cap biotech stocks Cardiome Pharma Corp (NASDAQ: CRME), Oncolytics Biotech, Inc (NASDAQ: ONCY), Vital Therapies Inc (NASDAQ: VTL) and TNI BioTech (OTCMKTS: TNIB) have all been producing their share of news this week for investors and traders alike to trade on. Moreover and while some 42 ��ife sciences��companies have gone public raising about $3 billion from investors so far this year, there are a growing number of biotechs pulling the plug on upcoming IPOs who are citing market conditions. With that in mind, here is a look at important news from the biotech sector and small cap biotech stocks this week:

• [By Bryan Murphy]

  Back on March 13th I penned some less-than-well-received thoughts on Cardiome Pharma Corp. (NASDAQ:CRME). Basically, I was warning that CRME was just one stumble away from a fairly significant selloff. Given that so many traders were a fan of the biotech stock at the time, merely posing the possibility of a dip was something of a threat to my life and limb.

Hot Asian Stocks To Watch For 2014: Ellington Financial LLC (EFC)

Ellington Financial LLC (EFC) is a specialty finance company, which specializes in acquiring and managing mortgage-related assets. As of December 31, 2011, its targeted assets included residential mortgage-backed securities (RMBS), backed by prime jumbo, Alternative A-paper (Alt-A), manufactured housing and subprime residential mortgage loans (non-Agency RMBS); RMBS for which the principal and interest payments are guaranteed by a United States Government agency or a United States Government-sponsored entity (Agency RMBS); mortgage-related derivatives; commercial mortgage-backed securities (CMBS), commercial mortgage loans and other commercial real estate debt, and corporate debt and equity securities and derivatives. It also acquires and manages other types of mortgage-related assets and financial assets, such as residential whole mortgage loans, asset-backed securities (ABS), backed by consumer and commercial assets, non-mortgage-related derivatives and real property.

Non-Agency RMBS

The Company acquires non-Agency RMBS backed by prime jumbo, Alt-A, manufactured housing and subprime residential mortgage loans. Its non-Agency RMBS holdings include investment-grade and non-investment grade classes. Non-Agency RMBS are debt obligations issued by private originators of or investors in residential mortgage loans. Non-Agency RMBS are issued as CMOs and are backed by pools of whole mortgage loans or by mortgage pass-through certificates. Non-Agency RMBS are securitized in senior/subordinated structures, or in excess spread/over-collateralization structures. In senior/subordinated structures, the subordinated tranches absorb all losses on the underlying mortgage loans before any losses are borne by the senior tranches.

Agency RMBS

The Company�� assets in this asset class consist of whole pool pass-through certificates, the principal and interest of which are guaranteed by Federal National Mortgage Association (Fannie Mae), Federal Home Loan Mortgage Cor! poration (Freddie Mac), or Government National Mortgage Association (Ginnie Mae), and which are backed by adjustable rate mortgages (ARMs), hybrid ARMs or fixed-rate mortgages. Mortgage pass-through certificates are securities representing undivided interests in pools of mortgage loans secured by real property where payments of both interest and principal, plus pre-paid principal, on the securities are made monthly to holders of the security, in effect passing through monthly payments made by the individual borrowers on the mortgage loans that underlie the securities, net of fees paid to the issuer/guarantor and servicers of the securities. Whole pool pass-through certificates are mortgage pass-through certificates that represent the entire ownership of a pool of mortgage loans.

In addition to investing in specific pools of Agency RMBS, the Company utilizes forward-settling purchases and sales of Agency RMBS where the underlying pools of mortgage loans are to be announced mortgage-backed securities (MBS) (TBAs). Pursuant to these TBA transactions, it agrees to purchase or sell, for future delivery, Agency RMBS with certain principal and interest terms and certain types of underlying collateral. It uses TBAs for hedging purposes. It engages in TBA transactions for purposes of managing certain risks associated with its long Agency RMBS and its non-Agency RMBS.

Mortgage-Related Derivatives

The Company takes long and short positions in various mortgage-related derivative instruments, including credit default swaps. A credit default swap is a credit derivative contract in which one party (the protection buyer) pays an ongoing periodic premium (and often an upfront payment as well) to another party (the protection seller) in return for compensation for default (or similar credit event) by a reference entity. In this case, the reference entity can be an individual MBS or an index of several MBS, such as an ABX Index, PrimeX or a CMBX Index.

CMBS

CMBS ar! e mortgage-backed securities collateralized by loans on commercial properties. CMBS issued are fixed rate securities backed by fixed rate loans made to multiple borrowers on a range of property types, though single-borrower CMBS and floating-rate CMBS have also been issued. Commercial mortgage loans are loans secured by liens on commercial properties, including retail, office, industrial, hotel and multifamily properties. Commercial real estate loans may also be structured into more complicated senior/subordinate structures, including those providing for multiple B-Note or multiple mezzanine loan senior/subordinate components.

Corporate Debt and Equity Securities and Derivatives

For hedging purposes, the Company takes short positions in corporate debt and equity (including indices on corporate debt and equity) by entering into derivative contracts, such as credit default swaps, total return swaps and options. These hedges reference corporations (such as financial institutions that have substantial mortgage-related exposure) or indices whose performance has a degree of correlation with the performance of its portfolio. Given this correlation, a short position with respect to such corporations or indices provides a hedge to its portfolio of MBS as a whole.

Other Assets

The Company from time to time acquires other mortgage-related and financial assets, which include residential whole mortgage loans, ABS backed by consumer and commercial assets and real property. It also acquires real property interests, such as single family and multifamily residential properties.

Advisors' Opinion:

• [By Luke Jacobi]

  Ellington Financial LLC (NYSE: EFC) was down, falling 4.4 percent to $23.53 after the company priced 8 million shares at $23.92 per share.

  Commodities

  Although equities have been flat, the same cannot be said for the commodity market. Crude futures shot higher Wednesday, following yesterday’s sharp sell off. At last check, WTI futures were up 2.7 percent to $95.37 and Brent futures gained 2.1 percent to $102.45.

Hot Asian Stocks To Watch For 2014: News Corporation(NWSA)

News Corporation operates as a diversified media company worldwide. Its Cable Network Programming segment produces and licenses news, business news, sports, general entertainment, and movie programming for distribution through cable television systems and direct broadcast satellite operators primarily in the United States, Latin America, Europe, and Asia. The company?s Filmed Entertainment segment produces and acquires live-action and animated motion pictures for distribution and licensing in entertainment media, as well as produces and licenses television programming worldwide. Its Television segment operates 27 broadcast television stations in the United States. The company?s Direct Broadcast Satellite Television segment distributes programming services via satellite and broadband directly to subscribers in Italy. Its Publishing segment provides newspapers and information services, such as publishing national newspapers in the United Kingdom, approximately 146 newspapers in Australia, and a metropolitan and a national newspaper in the United States; book publishing services, including the publishing of English language books worldwide; and integrated marketing services comprising the publishing of free-standing inserts, which are marketing booklets containing coupons, rebates, and other consumer offers, as well as provides in-store marketing products and services, primarily to consumer packaged goods manufacturers in the United States and Canada. The company also sells advertising, sponsorships, and subscription services on the company?s various digital media properties and outdoor advertising space on various media primarily in Russia and eastern Europe; and provides data systems and professional services that enable teachers to use data to assess student progress and deliver individualized instructions. News Corporation was founded in 1922 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Jon Friedman]

  The new News Corp. (NASDAQ: NWSA  ) has a lot to prove as a stand-alone company.

  This News Corp. is the product of a split between the former media conglomerate also known as News Corp., which then consisted of one company containing ample entertainment, broadcasting, and print-media assets. When the old News Corp. CEO Rupert Murdoch chose to divide it into two separate companies, with trading commencing on July 1, the new News Corp. inherited the print-journalism assets, including The Wall Street Journal and the�perennially money-bleeding�New York Post, as well as book publisher HarperCollins and Dow Jones (for which I worked, as a media columnist at MarketWatch, from 2007 till early this year).

• [By Lisa Levin]

  News Corporation (NASDAQ: NWSA) shares gained 0.61% to touch a new 52-week high of $18.13. 21st Century Fox announced its plans to sell its 47% stake in Star China TV.

• [By WALLSTCHEATSHEET]

  News Corp. is a multimedia giant that is able to reach and affect audiences all over the world. The stock has been a big winner over the last several years and is currently digesting gains for a strong run. Over the last four quarters, investors in the company have been upbeat as earnings and revenue figures have been rising. Relative to its strong peers and sector, News Corp. has been a year-to-date performance leader. Look for News Corp. to continue to OUTPERFORM.

Hot Asian Stocks To Watch For 2014: Braskem SA (BRKM5)

Braskem SA is a Brazil-based company primarily engaged in the manufacture of basic petrochemical products. The Company operates in five segments: Basic petrochemicals, Polyolefins, Vinyls, International businesses and Chemical Distribution. The Company�� products portfolio includes ethylene, propylene, butadiene, toluene, xylene, benzene, gasoline, diesel oil, liquefied petroleum gas (LPG), as well as thermoplastic resins, such as polyethylene (PE), polypropylene (PP) and polyvinyl chloride (PVC). Additionally, Braskem is also engaged in the import and export of chemicals, petrochemicals and fuels; the production, supply and sale of utilities, such as steam, water, compressed air, industrial gases, as well as the provision of industrial services, and the production, supply and sale of electric energy for its own use and use by other companies. The Company also invests in other companies, either as a partner or shareholder. Advisors' Opinion:

• [By Harry Suhartono]

  Brazil�� Ibovespa rose for a third day as traders pared bets on higher borrowing costs in Brazil, boosting the outlook for companies that sell in the local market. B2W Cia. Digital led gains among retailers, with Lojas Americanas SA (LAME3) and Natura Cosmeticos SA (NATU3) also trading higher. Petrochemicals producer Braskem SA (BRKM5) was the worst performer on the equity gauge after O Estado de S.Paulo reported Petroleo Brasileiro SA (PETR4) is seeking to raise prices of naphtha sold to the company by 5 percent.

Hot Asian Stocks To Watch For 2014: Medallion Financial Corp.(TAXI)

Medallion Financial Corp., through its subsidiaries, operates as a specialty finance company in the United States. The company engages in originating, acquiring, and servicing loans that finance taxicab medallions and various types of commercial businesses. It offers commercial loans to finance the purchase of the equipment and related assets necessary to open a new business, or the purchase or improvement of an existing business; asset-based loans to small businesses; and secured mezzanine loans to businesses in various industries, including manufacturing and various service providers. The company also raises deposits; originates consumer loans for the purchase of recreational vehicles, boats, motorcycles, trailers, and hearing aids; and conducts other banking activities. In addition, it provides other debt, mezzanine, and equity investment capital to companies in various industries. The company was founded in 1995 and is headquartered in New York, New York.

Advisors' Opinion:

• [By Lawrence Meyers]

  That�� the case with Medallion Financial Corporation (TAXI). This neat little company is primarily focused on the financing of taxi cab licenses in major cities like New York. It does other specialty lending as well — such as asset-backed loans for luxury vehicles like boats and art. But its bread and butter has been the taxi business.

Hot Asian Stocks To Watch For 2014: FreeSeas Inc.(FREE)

FreeSeas Inc., through its subsidiaries, operates as a bulk transportation company. The company transports various drybulk commodities, including iron ore, grain, and coal, as well as bauxite, phosphate, fertilizers, steel products, cement, sugar, rice, and minor bulks. As of December 31, 2010, it owned and operated nine vessels, including seven Handysize and two Handymax dry bulk carriers. The company was formerly known as Adventure Holdings S.A. and changed its name to FreeSeas Inc. in April 2005. FreeSeas Inc. was incorporated in 2004 and is based in Piraeus, Greece.

Advisors' Opinion:

• [By Rebecca McClay]

  And dry bulk shippers like FreeSeas Inc. (Nasdaq: FREE), Seanergy Maritime Holdings Corp. (Nasdaq: SHIP), and Eagle Bulk Shipping Inc. (Nasdaq: EGLE) are noting big gains today as shipping rates strengthen. FREE is up 8%, SHIP is up 13%, and EGLE is up 7% as capesize shipping rates increased overnight by about 10%, exceeding $20,000 for the first time since January 2012.

Hot Biotech Stocks To Invest In 2014

Popular Posts: 7 Biotechnology Stocks to Buy Now15 Oil and Gas Stocks to Sell Now13 “Triple A” Stocks to Buy Recent Posts: 10 Worst “Strong Sell” Stocks This Week ��ICA RCII YZC and more 5 Energy Services Stocks to Buy Now 7 Restaurant and Resort Stocks to Buy Now View All Posts

This week, seven restaurant and resort stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Hot Electric Utility Companies For 2015: Synageva BioPharma Corp (GEVA)

Synageva BioPharma Corp., incorporated in 1993, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products. It has several protein therapeutics in development, including two enzyme replacement therapies for lysosomal storage disorders and two programs for life-threatening genetic conditions. Its lead program, SBC-102, recombinant human lysosomal acid lipase (LAL), is its advanced pipeline program in clinical development for LAL Deficiency. This enzyme is responsible for the metabolism of cholesteryl esters and triglycerides that are delivered to lysosomes by a variety of routes, including low-density lipoprotein receptor mediated endocytosis. On November 2, 2012, Trimeris, Inc. merged with Synageva BioPharma Corp.

SBC-102 is produced by recombinant deoxyribonucleic acid (DNA) technology in egg white using its protein manufacturing platform. The Company has initiated natural history studies in approximately 20 countries. In addition to SBC-102, it is progressing protein therapeutic programs for other rare diseases, which are at different stages of preclinical development. These include two enzyme replacement therapies for other lysosomal storage disorders and two programs for other rare life-threatening conditions. As of December 31, 2011, its product candidate pipeline included SBC-102, SBC-103, SBC-104, SBC-105 and SBC-106.

SBC-104 is an extracellular protein that targets a severe, rare genetic condition. SBC-105 is an enzyme replacement therapy being developed to treat a severe, rare metabolic disorder. SBC-106 is a protein therapy that targets a severe and rare genetic condition.

Advisors' Opinion:

• [By Ben Levisohn]

  Somaiya and team named Gilead and�Neurocrine Biosciences (NBIX) their top picks, hile putting Buy ratings on Celgene, Biogen Idec, Alexion (ALXN), Incyte (INCY), Pharmacyclics (PCYC) and Synageva (GEVA). BioMarin (BMRN), Infinity Pharmaceuticals (INFI) and Amgen (AMGN) earned Neutral ratings.

Hot Biotech Stocks To Invest In 2014: Cannabis Science Inc (CBIS)

Cannabis Science, Inc., incorporated on May 4, 2007, is a development-stage company. The Company is engaged in the creation of cannabis-based medicines, both with and without psychoactive properties, to treats disease and the symptoms of disease, as well as for general health maintenance. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products.

Advisors' Opinion:

• [By John Udovich]

  One almost has to feel sorry for old school small cap marijuana stocks like Medical Marijuana Inc (OTCMKTS: MJNA), Cannabis Science Inc (OTCMKTS: CBIS) and�Hemp Inc�(OTCMKTS: HEMP) which have been around awhile and increasingly have to contend with the marijuana newswires getting flooded with news from every small cap OTC stock along with�your mother�� uncle�� fifth cousin trying to grab a piece of the marijuana�hype. We alone had two specific articles (Small Cap Marijuana Stocks Aiming for a High With News: MCIG, FRTD & SKTO�and Four Marijuana Small Caps Giving Investors Highs or Lows: ENRT, VMGI, NVLX & RTXBQ) covering about half a dozen different wannabe marijuana stocks with news for�just this week along with another article (Putting My Call on Latteno Food in Perspective, Take-Two (LATF, MJNA, ERBB)) about another small cap that�� infusing food with weed.�

Hot Biotech Stocks To Invest In 2014: Savient Pharmaceuticals Inc(SVNT)

Savient Pharmaceuticals, Inc., a specialty biopharmaceutical company, focuses on developing KRYSTEXXA, a biologic PEGylated uricase in the United States. The KRYSTEXXA is being developed as a treatment for chronic gout in patients refractory to conventional therapy. The company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. It sells its products directly to drug wholesalers. The company, formerly known as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in June 2003. Savient Pharmaceuticals, Inc. was founded in 1980 and is headquartered in East Brunswick, New Jersey.

Advisors' Opinion:

• [By James E. Brumley]

  Since 2008's implosion from the stock, the interest in Savient Pharmaceuticals Inc. (NASDAQ:SVNT) has been waning. There was a brief burst of bullishness in September of last year, which stirred the bullish pot a little. But, when SVNT started to fade in October of that year - just as quickly as it had perked up - what lingering hopes there were for the stock finally started to melt away. By the middle of this year, pretty much everyone had written Savient Pharmaceuticals off as a lost cause. Big mistake. Over the last few days, SVNT has almost wiggled its way buck into a bullish zone.

Hot Biotech Stocks To Invest In 2014: Biodel Inc (BIOD)

Biodel Inc. (Biodel), incorporated on December 3, 2003, is a development-stage speciality biopharmaceutical company focused on the development and commercialization of treatments for diabetes. The Company develops its product candidates by applying its formulation technologies to existing drugs. Its advanced program involves developing formulations of injectable recombinant human insulin (RHI). In addition to its ultra-rapid-acting insulin formulations, the Company has developed prototype formulations of a liquid glucagon, a basal insulin and a glucose responsive insulin, in each case for use by patients with diabetes. RHI-based formulation known as Linjeta was the subject of a New Drug Application (NDA).

The Company has two pivotal Phase III clinical trials with its preferred commercial formulation of Linjeta prior to re-submitting the NDA. In August 2011, it completed patient visits and analyzed top-line data from the first Phase 1 clinical trial of two RHI-based formulations. The trial was a single-center, randomized, double-blind, three-period crossover trial in 18 subjects with Type 1 diabetes. The purpose of the trial was to evaluate the pharmacokinetic and pharmacodynamic characteristics and injection site toleration of BIOD-105 and BIOD-107, as compared to the insulin analog marketed as Humalog. The Company conducted Phase I, Phase II and Phase III clinical trials comparing the performance of its Linjeta formulation of RHI to either Humulin, which is a branded formulation of RHI or Humalog. Its pivotal Phase III clinical trials were open-label, parallel group, randomized trials conducted at centers in the United States, Germany and India.

The Company competes with Eli Lilly, Novo Nordisk, Sanofi-Aventis, Halozyme Therapeutics, Inc. and MannKind Corporation.

Advisors' Opinion:

• [By Monica Gerson]

  Biodel (NASDAQ: BIOD) is expected to post a Q1 loss at $0.24 per share.

  First Majestic Silver (NYSE: AG) is estimated to post its Q1 earnings at $0.10 per share on revenue of $63.35 million.

• [By Roberto Pedone]

  One under-$10 specialty biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Biodel (BIOD), which is focused on the development and commercialization of innovative treatments for diabetes. This stock has been hit hard by the bears over the last three months, with shares down by 24%.

  If you take a look at the chart for Biodel, you'll notice that this stock is ripping higher here right off its 50-day moving average of $2.32 a share with strong upside volume. Volume on Thursday has so far registered over 750,000 shares, which is well above its three-month average action of 445,084 shares. This move is quickly pushing shares of BIOD within range of triggering a big breakout trade.

  Traders should now look for long-biased trades in BIOD if it manages to break out above some near-term overhead resistance levels at $2.52 to $2.60 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 445,084 shares. If that breakout triggers soon, then BIOD will set up to re-test or possibly take out its next major overhead resistance levels $3 to its 200-day moving average of $3.39 a share. Any high-volume move above $3.39 will then give BIOD a chance to tag $4 a share.

  Traders can look to buy BIOD off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $2.10 a share. One can also buy BIOD off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

Hot Biotech Stocks To Invest In 2014: Elan Corporation PLC (ELN)

Elan Corporation, plc (Elan), incorporated in December 1969, is a neuroscience-based biotechnology company. The Company is focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. Elan�� business focuses on neurodegenerative diseases, such as Alzheimer�� disease and Parkinson�� disease; autoimmune diseases, including MS and Crohn�� disease and neo-epitope based targets for treatments across a range of therapeutic indications. Tysabri is a treatment for MS and Crohn�� disease that the Company markets and distributes with Biogen Idec. On September 16, 2011, Elan sold its EDT business to Alkermes, Inc. In November 2011, Elan launched a collaboration with the University of Cambridge, England, the Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre). On December 21, 2012, the Company completed the demerger of Prothena Corporation plc. In April 2013, it closed the TYSABRI (natalizumab) Collaboration Transaction with Biogen Idec.

Tysabri

Tysabri, which is an alpha-4 integrin inhibitor, is a therapy for MS, a neurological disorder involving central nervous system dysfunction among adults. Tysabri is approved in more than 65 countries. Tysabri is approved in the United States as a monotherapy for relapsing forms of MS, for patients who have had an inadequate response to, or are unable to tolerate, an alternative MS therapy. In the European Union, it is approved for relapsing-remitting MS (RRMS) in adult patients who have failed to respond to beta interferon or have rapidly evolving, severe RRMS. As of December 31, 2011, there were approximately 64,400 patients on Tysabri therapy worldwide.

In June 2011, the European Commission (EC) approved the inclusion of the anti-JCV antibody status as an additional factor in stratifying patients at risk for developing PML in the Summary of Product Characteristics��(SmPC) for Tysabri in the European Union. The Company has developed a two-step ! enzyme-linked immunosorbent assay (ELISA), STRATIFY JCV, with Biogen Idec. The assay detects anti-JCV antibodies in the blood of patients, and is commercially available in Europe. In January 2012, the FDA cleared the assay for commercial use in the United States. As of December 31, 2011, over 80,000 tests had been administered using the assay. Tysabri is marketed and distributed by Elan and Biogen Idec. The Company�� research group, Neotope, is focused on creating monoclonal antibodies based on neo-epitope targets for the treatment of a range of therapeutic indications.

Beta Amyloid Immunotherapies (AIP)

Beta amyloid immunotherapy includes the treatment of Alzheimer�� disease by inducing or enhancing the body�� immune response in order to clear toxic species of beta amyloid from the brain. The AIP includes bapineuzumab (intravenous and subcutaneous delivery) and ACC-001, as well as other compounds. Bapineuzumab is an experimental humanized monoclonal antibody delivered intravenously that is being studied as a treatment for mild to moderate Alzheimer�� disease. It is designed to provide antibodies to beta amyloid directly to the patient (passive immunotherapy).

ELND005, an A� Aggregation Inhibitor

The small molecule ELND005 (Scyllo-inositol) is a beta amyloid anti-aggregation agent. Preclinical data suggest that ELND005 may act through the mechanism of preventing and reversing the fibrilisation of beta amyloid (the aggregation of beta amyloid into clumps of insoluble oligomers). ELND005 may have additional applications in psychiatric indications, such as bipolar disorder. In November 2011, the Company entered into a manufacturing agreement for the supply of the active pharmaceutical ingredient for ELND005 with Lonza Group AG.

Neotope Biosciences Limited

Neotope Biosciences Limited (Neotope) is the Company�� wholly owned subsidiary that focuses on the discovery and development of antibodies to neo-epitope related targ! ets for t! he treatment of a range of indications. It includes amyloidosis, diabetes, cancer and macular degeneration. Neotope�� portfolio of targets includes alpha-synuclein for the potential treatment of synucleinopathies, such as Lewy body dementia and Parkinson�� disease, tau for Alzheimer�� disease and other tauopathies. It also has a program for type 2-diabetes.

Onclave Therapeutics Limited

Elan�� wholly owned subsidiary Onclave Therapeutics Limited (Onclave) was formed to develop assets originating from Elan that have application in oncology related diseases. Onclave�� program, NEOD001, which originated from Neotope, is being investigated for the treatment of AL amyloidosis, which is a fatal disease involving abnormal accumulation of amyloid in organs and tissue. During the year ended December 31, 2011, Onclave filed for orphan drug designation of NEOD001. Onclave�� pipeline includes additional compounds with relevance in diverse cancer indications.

The Company competes with Biogen Idec, Bayer Schering Pharma AG, Bayer Schering Pharma, Merck Serono, Pfizer, Teva Neurosciences, Inc., Sanofi-Aventis and Novartis AG.

Advisors' Opinion:

• [By WALLSTCHEATSHEET]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with neurodegenerative and autoimmune diseases. The stock has struggled over the last couple of years and looks to be comfortable at these prices. Over the last four quarters, investors in the company have been disappointed as earnings have decreased while revenue figures have increased. Relative to its peers and sector, Elan has been a year-to-date performance leader. WAIT AND SEE what Elan does in coming quarters.

• [By Rich Duprey]

  After months of fighting off the advances of unwanted suitor Royalty Pharma, Irish biotech Elan (NYSE: ELN  ) finally got an offer it couldn't refuse -- from drugmaker Perrigo (NYSE: PRGO  ) .

• [By WALLSTCHEATSHEET]

  Elan is a biotechnology company that is looking for ways to improve and better the lives of people with disruptive diseases. The company is now set to be bought-out by Perrigo. The stock has been rising over the last several months, and is now trading at prices not seen for five years. Over the last four quarters, investors have had mixed feelings about the company, as earnings have been mixed, while revenue figures have been improving. Relative to its peers and sector, Elan has been a year-to-date performance leader. Look for Elan to OUTPERFORM.

Hot Biotech Stocks To Invest In 2014: Celgene Corp (CELG)

Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.

Commercial! Stage Products

REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.

REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.

THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.

ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.

Preclinical and Clinical-Stage Pipeline

The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.

The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).

The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.

At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.

The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.

The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).

Advisors' Opinion:

• [By Ben Levisohn]

  While we lean positive on the large cap names across the board, including Neutral-rated names [Biogen (BIIB)] and [Celgene (CELG)], we single out [Gilead Sciences (GILD)] as our favourite into YE13e and into 2014. Among mid caps, we favor…[Medivation (MDVN).]

• [By Mani]

  Celgene Corporation (NASDAQ:CELG) plans to release its third quarter financial results on�Oct.24�and will host a conference call and live audio webcast on the same day at�9 a.m. ET�to discuss the financial and operational performance.

• [By Ben Levisohn]

  Phase-III trial data for Celgene’s (CELG) revlimid was published in the New England Journal of Medicine, and while the data was unchanged from a previous release, UBS analyst Matthew Roden still considers it good news for the stock. He explains why:

  �The pivotal MM-020 phase-3 study of Revlimid-dexamethasone (Rd) was published in last night’s New England Journal of Medicine. The data were unchanged from the presentation at the Dec-2013 ASH meeting. The accompanying editorial described the survival benefit as “modest but significant” and stated that continuous (long-duration) therapy is “preferable.” We think Rd is established as the standard at this point, though we wouldn�� be surprised to see Rd with Kyprolis (KRd) use in front line increase, based on highest-ever CR rates, since the ASPIRE trial showed KRd benefit in a randomized trial. We see upside to Revlimid estimates based on longer duration (K)Rd use.

  Bernstein’s Geoffrey Porges and Wen Shi assess the state of revlimid patent challenges in Europe:

  One of the major investment controversies for Celgene this year has been the Revlimid patent litigation in the US. We have written extensively on this topic, and concluded that the case will likely settle largely in Celgene’s favor in the next 6-8 months.1,2 We are also aware that several Revlimid patents, including a polymorph patent that expires in 2024, have been challenged in Europe. We have received investor questions about potential downside scenarios of earlier patent loss in Europe vs. the current expectation of 2024 as guided by Celgene in its recent 10-K filing. To address these questions, we consulted European patent attorneys and reviewed the ongoing patent challenges. Our analysis of the legal proceedings in Europe suggests that there is a realistic chance that the EU polymorph patent may be revoked; however, we believe the composition patent is solid and should provide pr

• [By Sean Williams]

  As I prefer to always start you off with the good news, let's turn our attention to Celgene (NASDAQ: CELG  ) , which, on Friday, announced that the European Commission had approved its oral relapsed and refractory rare blood cancer drug pomalidomide in combination with dexamethasone. Celgene will be launching the drug in Europe under the trade name Imnovid, and it'll be used in cases where patients have tried at least two previous cancer therapies. In late-stage trials, Imnovid delivered progression-free survival of 15.7 weeks, which was a dramatic improvement over the placebo. Worldwide peak sales estimates for the drug are around $1 billion, so this is certainly a good start.

Hot Biotech Stocks To Invest In 2014: Redhill Biopharma Ltd (RDHL)

Redhill Biopharma Ltd. is an Israel-based biopharmaceutical company. The Company is focused on the development and acquisition of therapeutic candidates. The Company�� pipeline consists of six late clinical development therapeutic candidates, two of which have completed bioequivalence clinical trials subject to review and approval by the United States Food and Drug Administration and, in some cases, regulatory authorities in other countries. The Company�� six clinical stage therapeutic candidates include RHB-101, RHB-102, RHB-103, RHB-104, RHB-105 and RHB-106.

RHB-101

RHB-101 is a treatment of hypertension, heart failure and left ventricular dysfunction (following myocardial infraction) by means of controlled release of an active ingredient known as carvedilol, which is designed to be administered to patients on a once-daily basis. RHB-101 is based on a patented technology for the controlled release of drugs administered orally.

RHB-102

RHB-102 is a once-daily controlled release oral formulation of ondansetron. RHB-102 utilizes a technology called CDT that uses salts to provide a controlled release of ondansetron.

RHB-103

RHB-103 is an oral thin film formulation of rizatriptan intended for the treatment of acute migraine headaches. Migraine is a neurovascular disorder (related to nerves and blood vessels) characterized by recurrent headaches in one side or both sides of the head.

The product is based on a technology called VersaFilm.

RHB-104

RHB-104 is an antibiotic combination therapy for the treatment of Crohn's disease (with a PIII clinical study underway), as well as Multiple Sclerosis (with an ongoing PIIa clinical study) and Rheumatoid Arthritis. RHB-104 is a combination of clarithromycin, clofazimine and rifabutin, three generic antibiotic ingredients, in a single capsule.

RHB-105

RHB-105, an antibiotics and proton pump inhibitor drug targeting Helico! bacter Pylori infection. RHB-105 is a combination of three approved drug products omeprazole, which is a proton pump inhibitor (the natural body pump that produces the gastric acids used for digesting the food in the stomach), and amoxicillin and rifabutin which are antibiotics. Chronic infection with Helicobacter pylori irritates the mucosal lining of the stomach and small intestine.

RHB-106

RHB-106, is a tablet for the preparation and cleansing of the gastrointestinal tract prior to the performance of abdominal procedures. Its abdominal procedures include diagnostic tests, such as colonoscopy, barium enema or virtual colonoscopy, as well as surgical interventions, such as laparotomy.

The company competes with GlaxoSmithKline, Sanofi-Aventis Groupe, Hoffman-La Roche Ltd, Merck and Co., Inc, Ferring Pharmaceuticals and Salix Pharmaceuticals Inc.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Vitran Corporation (NASDAQ: VTNC) announced today that it has entered into a definitive arrangement agreement with TransForce pursuant to which TransForce has agreed to acquire all of the outstanding common shares of Vitran not already owned by TransForce for US$6.50 in cash per share, in accordance with TransForce's prior proposal. To read the full news, click here. ReneSola (NYSE: SOL) today announced it signed a Memorandum of Intent (MOI) to sell three utility-scale projects in Western China, with a total capacity of 60MW, to Jiangsu Akcome Solar Science & Technology Co on December 30, 2013. To read the full news, click here. Cooper Tire & Rubber Company (NYSE: CTB) today announced it has terminated the merger agreement with Apollo Tyres (NSE:ApolloTYRE). To read the full news, click here. RedHill Biopharma (NASDAQ: RDHL) today announced that it has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC, for the sale of RedHill's American Depository Shares and warrants in a private placement transactionor a total sum of $6.0 million. To read the full news, click here.

  Posted-In: Guggenheim US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Top Restaurant Stocks To Invest In 2014

Starbucks (NASDAQ: SBUX  ) had better watch its back. Literally.

Earlier this month, the coffeehouse chain announced a plan to expand its business significantly in Indonesia and the Philippines, opening 100 new stores in the former over three years and 100 new stores in the latter over four. Today, the company's archrival, Dunkin' Brands (NASDAQ: DNKN  ) is following hard on Starbucks' heels with an announcement that it, too, is headed to Southeast Asia.

Granted, for now Dunkin' says it's only entering the Filipino market, and not Indonesia. Granted, too, Dunkin' is spearheading its move into the country with its Baskin-Robbins brand, rather than with its coffee-and-donut shops. But still -- where Starbucks has trodden, Dunkin' is following.

Dunkin' says its plan is to develop the B-R brand in the Philippines, opening as many as 50 stores in the island nation over the next five years. It's signed a master licensing agreement with local operator IceDream to help with the expansion, noting that the company has "a deep understanding of the Filipino consumer and a proven track record of success in the local restaurant industry."

Best Freight Stocks To Watch For 2015: Popeyes Louisiana Kitchen Inc (PLKI)

Popeyes Louisiana Kitchen Inc, formerly AFC Enterprises, Inc. incorporated on July 27, 1992, develops, operates, and franchises quick-service restaurants (QSRs or restaurants) under the trade names Popeyes Chicken & Biscuits and Popeyes Louisiana Kitchen (collectively Popeyes). Within Popeyes, it manages two business segments: franchise operations and ompany-operated restaurants. Within the QSR industry, Popeyes distinguishes itself with a Louisiana style menu, which features spicy chicken, chicken sandwiches, chicken tenders, fried shrimp and other seafood, red beans and rice and other regional items. As of December 25, 2012, the Company operated and franchised 2,104 Popeyes restaurants in 47 states, the District of Columbia, Puerto Rico, Guam, the Cayman Islands and 26 foreign countries. As of December 25, 2012, of its 1,634 domestic franchised restaurants, approximately 70% were concentrated in Texas, California, Louisiana, Florida, Illinois, Maryland, New York, Georgia, Virginia and Mississippi. Of its 425 international franchised restaurants, approximately 60% were located in Korea, Canada, and Turkey. Of its 45 Company-operated restaurants, approximately 80% were concentrated in Louisiana and Tennessee. In November 2012, the Company acquired 27 restaurants in Minnesota and California.

As of December 25, 2012, the Company had 340 franchisees operating restaurants within the Popeyes system. During the fiscal year ended December 25, 2012 (fiscal 2012), the Popeyes system opened 141 restaurants, which included 75 domestic and 65 international restaurants. During fiscal 2011, the Popeyes system permanently closed 75 restaurants, resulting in 66 net restaurant openings, compared to 65 net openings. As of December 25, 2012, it leased 12 restaurants and subleased 44 restaurants to franchisees. In addition, it leased three properties to unrelated third parties. Of the restaurants leased or subleased to franchisees, 29 were located in Texas and 16 were located in Georgia. On November 7, 2012,! the Company entered into a new agreement with the King Features Syndicate Division of Hearst Holdings, Inc., licensor of the Popeye the Sailorman and associated cartoon characters.

Advisors' Opinion:

• [By Mark Yagalla]

  As the fast-food wars heat up, restaurants are getting more creative with their menu items. One item that is getting a lot of attention is the waffle. Two restaurant chains that have introduced their own variations of the waffle are Taco Bell, owned by Yum! Brands (NYSE: YUM  ) �and Popeyes Louisiana Kitchen (NASDAQ: PLKI  ) . Taco Bell has made the Waffle Taco a centerpiece of its new breakfast menu. Meanwhile, Popeyes is bringing back its popular Chicken Waffle Tenders. Could the waffle be the answer and boost same-store sales for these restaurants? If it is the answer, expect to see more variations of the waffle on many more menu boards.

Top Restaurant Stocks To Invest In 2014: Country Style Cooking Restaurant Chain Co Ltd (CCSC)

Country Style Cooking Restaurant Chain Co., Ltd. (CSC Cayman), incorporated on August 14, 2007, is a quick service restaurant chain in China. The Company offers delicious, everyday Chinese food. The Company conducts all of its restaurant operations through CSC China and its subsidiaries. As of June 30, 2012, it had 256 restaurants, including 124 restaurants in Chongqing municipality and 85 restaurants in Sichuan province.

Chongqing municipality and Sichuan province cover a region of 110 million people in Southwest China. CSC Cayman directly operates all of its restaurants. Its standard menu features its main dishes prepared in the Sichuan style, as well as a selection of other dishes, appetizers, desserts and beverages. The Company periodically offers new dishes and seasonal menu selections.

The Company competes with McDonald��, KFC and Yoshinoya.

Advisors' Opinion:

• [By CRWE]

  Country Style Cooking Restaurant Chain Co., Ltd (NYSE:CCSC), a fast-growing quick service restaurant chain in China, plans to release its unaudited second quarter 2012 financial results on Tuesday, August 14, 2012, after the market closes.

Top Restaurant Stocks To Invest In 2014: Darden Restaurants Inc (DRI)

Darden Restaurants, Inc. (Darden), incorporated in March 1995, is a company owned and full-service restaurant company. As of May 27, 2012, the Company operated through subsidiaries 1,994 restaurants in the United States and Canada. In the United States, it operated 1,961 restaurants in all 50 states, including 677 Red Lobster, 786 Olive Garden, 386 LongHorn Steakhouse, 46 The Capital Grille, 30 Bahama Breeze, 23 Seasons 52, eight Eddie V's Prime Seafood and three Wildfish Seafood Grille restaurants, and two test synergy restaurants, which house both a Red Lobster and Olive Garden restaurant in the same building. In Canada, the Company operated 33 restaurants, including 27 Red Lobster and six Olive Garden restaurants. Through subsidiaries, it owns and operates all of its restaurants in the United States and Canada, except for three restaurants located in Central Florida that is owned by joint ventures it manages. On November 14, 2011, it acquired eight Eddie V's Prime Seafood restaurants and three Wildfish Seafood Grille restaurants.

As of May 27, 2012, the Company had 28 restaurants outside the United States and Canada operated by independent third parties pursuant to area development and franchise agreements, including five LongHorn Steakhouse restaurants in Puerto Rico, 22 Red Lobster restaurants in Japan, and one Red Lobster restaurant in Dubai. During fiscal year ended May 27, 2012, it opened 89 net new restaurants in the United States and Canada.

Red Lobster

Red Lobster is a full-service dining seafood specialty restaurant operator in the United States. It offers a menu featuring fresh fish, shrimp, crab, lobster, scallops and other seafood. The menu includes a variety of specialty seafood and non-seafood entrees, appetizers and desserts. Red Lobster maintains different lunch and dinner menus and different menus across its trade areas.

Olive Garden

Olive Garden is a full service dining Italian restaurant operator in the United Stat! es. Olive Garden�� menu includes a range of authentic Italian foods featuring fresh ingredients and a wine list that includes a selection of wines imported from Italy. The menu includes flatbreads and other appetizers, soups, salad and garlic bread sticks, baked pastas, sauted specialties with chicken, seafood and fresh vegetables, grilled meats, and a variety of desserts. Olive Garden also uses coffee imported from Italy for its espresso and cappuccino.

LongHorn Steakhouse

LongHorn Steakhouse restaurants are full-service establishments serving both lunch and dinner. With locations in 35 states, primarily in the Eastern half of the United States, LongHorn Steakhouse restaurants feature a range of menu items, including signature fresh steaks, as well as salmon, shrimp, chicken, ribs, pork chops, burgers and prime rib.

The Capital Grille

The Capital Grille has locations in metropolitan cities in the United States. The Capital Grille offers seafood flown in daily and culinary specials created by its chefs. The restaurants feature a wine list offering over 350 selections, personalized service, and private dining rooms.

Bahama Breeze

Bahama Breeze restaurants bring guests the feeling of a Caribbean escape, offering the food, drinks and atmosphere found in the islands. The menu features Caribbean-inspired seafood, chicken and steaks, as well as signature specialty drinks. During fiscal 2012, it opened four Bahama Breeze restaurant.

Seasons 52

Seasons 52 is a grill and wine bar with seasonally inspired menus offering ingredients to meals that are lower in calories than comparable restaurant meals. It offers a wine list of more than 90 wines with approximately 60 available by the glass. As of May 27, 2012, there were 23 Seasons 52 restaurants in the United States.

Synergy restaurant

Synergy restaurant houses both a Red Lobster and Olive Garden restaurant in the same building, but ! with sepa! rate front doors, dining rooms and brand-specific menus. It opened a second synergy test location during fiscal 2012.

Advisors' Opinion:

• [By Dimitra DeFotis]

  Darden Restaurants (DRI) said Friday it will sell the struggling Red Lobster business to Golden Gate Capital for $2.1 billion in cash. Darden shares were down 3.6% to $48.82 in late afternoon trading following the news, which has some activist investors quite steamed.

• [By Ben Levisohn]

  Oppenheimer, meanwhile, highlights Darden Restaruants’ (DRI) tough summer. Brian Bittner and Michael Tamas write:

  We reduce 1Q14E EPS (Jun-Aug) to $0.63 vs. Street’s $0.75. Consensus likely to come down to $0.70 range after several outliers in $0.80+ range adjust. We model -3.4% comps for the Big 3 in 1Q14E, vs. sell-side’s current -0.6%…

Top Restaurant Stocks To Invest In 2014: Sodexo SA (SW)

Sodexo SA, (formerly Sodexho Alliance SA), is a global provider of services in three primary business areas: The On-site Services Solutions offer various services that range from food services to construction management, reception to the maintenance of scanners and laboratory equipment, management of data centers, leisure cruises and provides housekeeping to rehabilitation services at correctional facilities. The Motivation Solutions division provides passes and vouchers, comprising Restaurant Pass, Gift Pass, Sport Pass, Training Voucher, Service Card and Book Card, among others. The Company also provides Personal and Home Services in the form of childcare, tutoring, concierge services and in-home service care facilities. The Company is present in 80 countries in a number of geographic areas, such as North America, South America, Continental Europe and United Kingdom and Ireland. Advisors' Opinion:

• [By Glenwoods]

  Recently giant food conglomerate, Cargill announced it had partnered with the Swiss biosynthetic pharmaceutical company, Evolva (EVE:SW), to develop a more consistent and less expensive stevia sweetener via Evolva�� microbial fermentation-based process.� This is big news for the future of stevia because a microbial fermentation-based process does not have to rely on soil conditions or weather, and stevia can be manufactured anywhere, thus having the potential of guaranteeing an endless supply line of stevia.� Through the microbial fermentation, the manufacturer has the capability to process the key sweet individual components of stevia using low-cost plant sugars, and allows for the individual components of stevia, regardless of how minute, to be developed creating blends in any volume, which then could open the door for these manufacturers to fine-tune its stevia to local tastes.� But what would be most attractive is that, because the fermentation process does not require the entire plant, the method could conceivably shave upwards of 70% off the cost of producing stevia extracts.�

Top Restaurant Stocks To Invest In 2014: Richoux Group PLC (RIC)

Richoux Group plc is a United Kingdom-based company engaged in the operation of restaurants. The Company has three segments: Richoux, Villagio Zippers and Dean�� Diner. Richoux restaurants operate in the areas of central London. The restaurants are open all day for breakfast, lunch, afternoon tea and dinner. The restaurants also offers patisserie. Zippers is a spacious, stylish and contemporary restaurant with a relaxed ambience. Dean's Diner offers a range of freshly prepared dishes. Villagio is a modern local Italian restaurant with a menu suitable for the whole family. The Company�� subsidiaries include Newultra Limited and Richoux Limited. Advisors' Opinion:

• [By Sally Jones]

  
  Richmont Mines Inc. (RIC)

  Down 70% over 12 months, Richmont Mines Inc. has a market cap of $56.23 billion, and trades with a P/B of 0.60.

• [By John Udovich]

  Small cap�paper stock�Verso Paper Corp (NYSE: VRS), trucking stock�Covenant Transportation Group, Inc (NASDAQ: CVTI) and gold mining stock Richmont Mines Inc (NYSEMKT: RIC) are among the best small cap stock performers for the�year and the best in their respective sectors because they are�up 390.7%, 224.7% and 215%, respectively, since the start of the year. Why has the paper, trucking and gold mining sector produced three top performing small cap stocks? Here are some answers:

Top Restaurant Stocks To Invest In 2014: Chanticleer Holdings Inc (HOTR)

Chanticleer Holdings, Inc., incorporated in 1999, is a business operator focused on expanding the Hooters casual dining restaurant brand in international markets. Chanticleer has rights to develop and operate Hooters restaurants in South Africa and has joint ventured with the current franchisee in Australia. The company also has franchise rights to develop Hungary and parts of Brazil while evaluating several additional opportunities internationally. During the year ended December 31, 2011, Chanticleer and a group of private equity investors acquired Hooters of America, Inc. (HOA). HOA is the franchisor and operator of over 450 Hooters restaurants in 44 states and 28 foreign countries. In October 2013, Chanticleer Holdings Inc purchased American Roadside Burgers, Inc. In December 12, 2013, Chanticleer Holdings Inc acquired a 51% interest in JF Restaurants LLC, an owner and operator of restaurants. In February 2014, it acquired Hooters' United States Pacific Northwest franchise rights and two existing restaurants in Oregon and Washington.

The Company operates in two business segments: Hooters franchise restaurants, and investment management and consulting services businesses. Hooters has also branched out to other areas, including licensing its name to a golf tour and the sale of packaged food in supermarkets. Its subsidiaries include Chanticleer Advisors, LLC, (Advisors), Avenel Ventures, LLC (Ventures), Avenel Financial Services, LLC (AFS), Chanticleer Holdings Limited (CHL), Chanticleer Holdings Australia Pty, Ltd. (CHA), Chanticleer Investment Partners, LLC (CIP), DineOut SA Ltd. (DineOut), Kiarabrite (Pty) Ltd (KPL), Dimaflo (Pty) Ltd (DFLO), Tundraspex (Pty) Ltd (TPL), Civisign (Pty) Ltd (CPL), Dimalogix (Pty) Ltd (DLOG) and Crown Restaurants Kft. (CRK).

South Africa

As of December 31, 2011, the Company had four Hooters locations in South Africa in Cape Town, Durban and Johannesburg (two locations), which are owned by four companies, which it control. The Com! pany formed a management company to operate the current South African Hooters locations. It owns 80% of the management company, with two members of local management owning the remaining 20%. The management company charges a management fee of 5% of net revenues to the Hooters locations in South Africa.

Other Countries

The Company has acquired development rights for Hooters in five states of Brazil, which would include Rio de Janeiro. It has applied to HOA for franchise rights in Hungary, where it own 80% of the entity the Company anticipate will hold the franchise rights and its local partner owns the remaining 20%. The Company has partnered with the Hooters franchisee in a joint venture in which it owns 49% and its partner 51%. The first Hooters restaurant under this joint venture (which would be the third Hooters restaurant open in Australia) opened in January 2012 in Campbelltown, a suburb of Sydney. It has a non-binding letter of intent with a franchisee to purchase 100% of an existing Hooters location.

Management and consulting services

The Company provides management and consulting services for small companies, which are seeking to become publicly traded. The Company also provides management and investment services for Investors LLC and Investors II, which are affiliates of the Company.

Advisors' Opinion:

• [By Konrad Kuhn]

  Chanticleer Holdings (HOTR), a franchisee of international Hooters restaurants, has exploded through its upside target prices; however, in our view, the stock has a long way to go, as it expands its restaurants abroad, and in the US.

• [By Chris Isidore]

  Restaurant chains are trying to hold the line on prices. Mark Allison, senior vice president of culinary operations at Chanticleer Holdings (HOTR), which operates the American Roadside Burger chain, said his chain raised prices about 12%, even though their beef costs are up even more than that.

Top Up And Coming Stocks To Invest In Right Now

Top Up And Coming Stocks To Invest In Right Now: Cray Inc(CRAY)

Cray Inc. engages in the design, development, manufacture, marketing, and service of high-performance computing (HPC) systems, known as supercomputers. Its product line includes Cray XE6 system, a massively parallel processing system; Cray XE6m supercomputer that incorporates its Cray Gemini network; Cray XMT supercomputer, a scalable massively multithreaded platform with a shared memory architecture that is suited for tasks, such as pattern matching, complex searches, scenario development, behavioral prediction, anomaly identification, and graph analysis; and Cray CX1 and CX1000 systems that are purpose-built for laboratories and university departments. The company?s products under development comprise Cray XE6 System enhancements; and next generation Cray XMT System. It also offers engineering services related to HPC systems and solutions, such as maintenance support services and technology-led professional services. Cray Inc. provides its products and services to gover nment agencies, academic institutions, and commercial entities in the United States, Canada, Europe, Japan, and the Asia-Pacific. The company was formerly known as Tera Computer Company and changed its name to Cray Inc. in 2000. Cray Inc. was founded in 1987 and is headquartered Seattle, Washington.

Advisors' Opinion:

• [By SA Pro Top Ideas]

  Stock Movers and Great Calls
  Alpha-Rich long and short ideas regularly move stocks and identify stocks that are about to move. Some notable recent calls subscribers had early access to:

  On July 24, Mike Williams explained why FreightCar America's (RAIL) shares could double by 2015 as it returned to historic profitability. Shares are +16.3% to date after a strong earnings report this week. Read article » Vince Martin said on June 17 that Cray's (CRAY) sell-off after Q1 earnings was way overdone, offering investors a great deal. After a strong earnings report last week, shares! now stand +45% from where they were before the article. Read article »

  To Come Today
  Don't forget to check your SA Pro dashboard later today for the latest Alpha-Rich ideas. Any thoughts to share on the latest Alpha-Rich ideas? Leave a comment here.
  
  SA Pro Editors
  …............
  
  The SA Pro team is Eli Hoffmann (Editor in Chief), Rachael Granby (Editorial Product Manager), Daniel Shvartsman, Samir Patel, Michael McDonald, and Jeffrey Fischer (Senior Pro Editors). You can reach us at pro-editors@seekingalpha.com.

• [By Jake L'Ecuyer]

  Equities Trading UP
  Cray (NASDAQ: CRAY) rose on Friday's session, gaining a staggering 36.87 percent to $41.02 after beating on the top and bottom lines, while boosting its fiscal year guidance.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/top-up-and-coming-stocks-to-invest-in-right-now-2.html

10 Best Machinery Stocks To Invest In Right Now

Popular Posts: 6 Oil and Gas Stocks to Buy Now16 Oil and Gas Stocks to Sell Now3 Machinery Stocks to Sell Now Recent Posts: 12 “Triple F” Stocks to Sell 8 “Triple A” Stocks to Buy 5 Stocks With Poor Analyst Earnings Revisions ��VCRA SUNE BONT VRTX PSEM View All Posts

This week, the overall grades of 17 oil and gas stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Top 5 Up And Coming Companies To Buy For 2015: Sterling Consolidated Corp (STCC)

Sterling Consolidated Corp., incorporated on January 31, 2011, is a holding company. The Company�� operations are conducted through its four subsidiaries: Sterling Seal & Supply, Inc. (Sterling Seal), ADDR Properties, LLC (ADDR), Q5 Ventures, LLC (Q5), and Integrity Cargo Freight Corporation (Integrity). The Company through its subsidiary, Sterling Seal engages primarily in the distribution and sale of O-rings, rubber seals, oil seals, custom molded rubber parts, custom Teflon parts, Teflon rods, O-ring cord, bonded seals, O-ring kits, and stuffing box sealant. The Company also owns real property through its subsidiaries ADDR and Q5. In addition, the Company�� subsidiary Integrity Cargo Freight Corporation (Integrity) is a freight forwarding business. In September 2013, the Company announced the acquisition of Superior Seals and Service in High Point, NC.

Sterling Seal sells directly to smaller distributors and original equipment manufacturers in need of seals. It offers a catalogue of standard sizes, and will take orders for special sizes not available in the standard catalogue. O-rings and the other products that Sterling Seal sells are used in a variety of industries, including automotive, pump, transmissions, oil and energy, machinery, and packaging. Integrity are primarily responsible for transporting products the Company order from its suppliers back to its warehouse in Neptune, NJ. After Sterling Seal confirms from its supplier that a product is ready to be picked up, Integrity Cargo is responsible for picking up the products and getting them to the dock and delivered to the Sterling Seal warehouse. ADDR owns a 28,000 square foot facility in Neptune, NJ. Q5 Ventures, LLC owns a 5,000 square foot facility in Apopka, Florida, which is used by Sterling Seal for its Florida operations.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Muscle Warfare International (OTCMKTS: MWAR), Portlogic Systems Inc (OTCMKTS: PGSY) and Sterling Consolidated Corp (OTCBB: STCC) were all the subject of a few paid promotions as recently as last week but they sure did not start the new week out right because all were sinking on Monday. So are these small cap stocks that are either the subject of promotions or investor awareness campaigns hot or not? Here is a quick reality check:

• [By Peter Graham]

  Small cap stocks Pulse Network Inc (OTCBB: TPNI), Sterling Consolidated Corp (OTCBB: STCC) and diaDexus, Inc (OTCMKTS: DDXS) have or could start to sizzle for investors. However, I should also mention that two of these stocks have been the subject of paid promotions while a third apparently has not been, and could be the real deal. With that in mind, here is a closer look along with a quick reality check about all three small caps to help you decide whether they are hot or not:

10 Best Machinery Stocks To Invest In Right Now: Deutz AG (DEZ)

DEUTZ AG is a Germany-based manufacturer of diesel engines. The Company produces engines with outputs of between 19 kilowatts (kW) and 520 kW for on-road as well as non-road applications. Its activities cover development, design, production, sales and services for diesel engines that are cooled by water, oil or air. DEUTZ AG divides its activities into two segments: DEUTZ Compact Engines and DEUTZ Customized Solutions. DEUTZ Customized Solutions segment focuses on air-cooled engines and large liquid-cooled engines with capacities of more than eight liters. The segment DEUTZ Compact Engines comprises liquid-cooled engines with capacities of less than four liters as well as engines with capacities of four to eight liters. The Company is the executive and operating company within the DEUTZ Group. It has a global reach with its production sites, ten distribution companies, nine sales offices, as well as over 800 distribution and service partners in more than 130 countries worldwide. Advisors' Opinion:

• [By Jonathan Morgan]

  RWE AG (RWE) jumped 6.4 percent, leading a gauge of utilities higher. Deutz AG (DEZ) plunged the most in more than two years after an investor sold a 8.4 percent stake in the manufacturer of diesel engines. ProSiebenSat.1 Media AG (PSM) dropped 1.1 percent after Telegraaf Media Groep NV sold its stake in the company.

10 Best Machinery Stocks To Invest In Right Now: The Greenbrier Companies Inc (GBX)

The Greenbrier Companies, Inc. (Greenbrier), formerly Greenbrier Oregon, Inc., incorporated on October 24, 2005, are the designers, manufacturers and marketers of railroad freight car equipment in North America and Europe, a manufacturer and marketer of ocean-going marine barges in North America and a provider of wheel services, railcar refurbishment and parts, leasing and other services to the railroad and related transportation industries in North America. The Company operates in three business segments: Manufacturing; Wheel Services, Refurbishment & Parts; and Leasing & Services.

The Manufacturing segment, operating from facilities in the United States, Mexico and Poland, produces double-stack intermodal railcars, conventional railcars, tank cars and marine vessels.

The Wheel Services, Refurbishment & Parts segment performs wheel, axle and bearing servicing; railcar repair, refurbishment and maintenance activities; as well as production and reconditioning of a variety of parts for the railroad industry in North America. The Leasing & Services segment owns approximately 11,000 railcars and provides management services for approximately 219,000 railcars for railroads, shippers, carriers, institutional investors and other leasing and transportation companies in North America. The Company produces rail castings through an unconsolidated joint venture.

Manufacturing

The Manufacturing segment manufactures a broad array of railcar types in North America which includes railcar types other than coal cars. The primary products offered by the Company include Intermodal Railcars, Conventional Railcars, Tank Cars, European Railcar Manufacturing and Marine Vessel Fabrication. The Company manufactures a range of intermodal railcars. The important intermodal product is articulated double-stack railcar. The double-stack railcar is designed to transport containers stacked two-high on a single platform. The Company produces a range of boxcars, which are used in t! he transport of forest products, automotive, perishables, general merchandise and commodities. It also produces covered hopper cars for the grain, energy, sand and cement industries as well as gondolas for the steel and metals markets and various other conventional railcar types, including Auto-Max car.

The Company�� European manufacturing operation produces a variety of railcar (wagon) types, including a line of pressurized tank cars for liquid petroleum gas and ammonia and non-pressurized tank cars for light oil, chemicals and other products. It also produces flat cars, coil cars for the steel and metals market, coal cars for both the continental European and United Kingdom markets, gondolas, sliding wall cars and automobile transporter cars.

The Company�� Portland, manufacturing facility, located on a deep-water port on the Willamette River, includes marine vessel fabrication capabilities. It manufactures range of Jones Act ocean-going and river barges for transporting merchandise between ports within the U.S. including conventional deck barges, double-hull tank barges, railcar/deck barges, barges for aggregates and other heavy industrial products and dump barges. It focuses on the ocean-going vessels and coal carrying river barges although the facility has the capability to compete in other marine related products.

Wheel Services, Refurbishment and Parts.

Wheel Services, Railcar Repair, Refurbishment and Component Parts Manufacturing segment operates in the independent wheel services, repair, refurbishment and component parts networks in North America, operating in 39 locations. The wheel shops, operating in 12 locations, provide complete wheel services including reconditioning of wheels, axles and roller bearings in addition to new axle machining and finishing and axle downsizing. Its network of railcar repair and refurbishment shops, operating in 23 locations, performs heavy railcar repair and refurbishment, as well as routi! ne railca! r maintenance. It is engaged in the repair and refurbishment of railcars for third parties, as well as of its own leased and managed fleet. Its component parts facilities, operating in four locations, recondition railcar cushioning units, couplers, yokes, side frames, bolsters and various other parts. It also produces roofs, doors and associated parts for boxcars.

Leasing and Services

Leasing-The Company offers flexible financing programs including operating leases and by the mile leases to the customers . The Company leases are full service leases whereby the Company is responsible for maintenance and administration. Maintenance of the fleet is provided, in part, through its own facilities and engineering and technical staff.

Management Services- management services business offers a broad array of software and services that include railcar maintenance management, railcar accounting services, such as billing and revenue collection, car hire receivable and payable administration, total fleet management including railcar tracking using software, administration and railcar remarketing. The Company provide management services for a fleet of approximately 230,000 railcars for railroads, shippers, carriers, institutional investors and other leasing and transportation companies in North America.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Top Headline
  The Greenbrier Companies (NYSE: GBX) reported a 13% gain in its fiscal second-quarter earnings. Greenbrier's quarterly profit surged to $15.6 million, or $0.50 per share, versus a year-ago profit of $13.8 million, or $0.45 per share. Excluding one-time items, it earned $0.51 per share. Its revenue climbed 88% to $502.2 million. However, analysts were expecting earnings of $0.60 per share on revenue of $508.69 million.

• [By Monica Gerson]

  The Greenbrier Companies, Inc.(NYSE: GBX) shares rose 9.51% to $54.00 in pre-market trading after the company reported better-than-expected earnings for its first fiscal quarter and raised its earnings forecast for FY 2015.

• [By Monica Gerson]

  The Greenbrier Companies (NYSE: GBX) is projected to report its Q3 earnings at $0.74 per share on revenue of $571.07 million.

  UniFirst (NYSE: UNF) is estimated to report its Q3 earnings at $1.42 per share on revenue of $349.24 million.

10 Best Machinery Stocks To Invest In Right Now: Flowserve Corp (FLS)

Flowserve Corporation, incorporated on May 1, 1912, is a manufacturer and aftermarket service provider of flow control systems. The Company develops and manufacture precision-engineered flows control equipment integral to the movement, control and protection of the flow of materials in its customers' critical processes. The Company operates in three segments: Engineered Product Division (EPD), which includes long leads time, custom and other engineered pumps and pump systems, mechanical seals, auxiliary systems and replacement parts and related services, Industrial Product Division (IPD), which includes pre-configured engineered pumps and pump systems and related products and services, and Flow Control Division (FCD), which includes engineered and industrial valves, control valves, actuators and controls and related services. Effective December 10, 2013, Flowserve Corp acquired Innovative Mag-Drive LLC.

Through the Company's manufacturing platform and global network of Quick Response Centers (QRCs), the Company offers an array of aftermarket equipment services, such as installation, advanced diagnostics, repair and retrofitting. The Company's product portfolio of pumps, valves, seals, automation and aftermarket services supports global infrastructure industries, including oil and gas, chemical, power generation and water management, as well as certain general industrial markets where the Company's products and services add value. The Company sells its products and services to more than 10,000 companies, including some of the engineering, procurement and construction firms (EPC), original equipment manufacturers, distributors and end users.

Engineered Product Division

The Company designs, manufactures, distributes and services engineered pumps and pumps systems, mechanical seals, auxiliary systems, replacement parts and related equipment. The business primarily consists of long lead time, engineered, configured products, which require extensive test requirements a! nd project management skills. EPD products and services are primarily used by companies that operate in the oil and gas, power generation, chemical, water management and general industries. The Company markets its pump and mechanical seals products through its global sales force and its regional QRCs and service and repair centers or through independent distributors and sales representatives. A portion of the Company's mechanical seal products are sold directly to original equipment manufacturers for incorporation into rotating equipment requiring mechanical seals. The Company's pump products are manufactured in a range of metal alloys and with a variety of configurations to meet the critical operating demands of the Company's customers.

The Company also manufactures a gas-lubricated mechanical seal that is used in high-speed compressors for gases pipelines and in the oil and gas production and process markets. The Company's products are manufactured at 29 plants worldwide, nine of which are located in Europe, 11 in North America, four in Asia Pacific and five in Latin America. The Company also conducts business through strategic foreign joint ventures. The Company has six unconsolidated joint ventures that are located in China, India, Japan, Saudi Arabia, South Korea and the United Arab Emirates, where a portion of its products are manufactured, assembled or serviced in these territories. The Company manufactures more than 40 different active types of pumps and approximately 185 different models of mechanical seals and sealing systems.

The Company's EPD products include between bearings pumps, which include single case- axially split, single case- radially split, double case; overhung pumps, which includes api process; positive displacement pumps, which includes multiphase, reciprocating and screw; mechanical seals and seal support systems, which includes gas barrier seals and dry-running seals, and specialty products, which includes nuclear pumps, nuclear seals, cryogenic p! umps, cry! ogenic liquid expander, hydraulic decoking systems, and API slurry pumps. The Company�� EPD Brand Names include BW Seals, Byron Jackson, Calder Energy Recovery Devices, Cameron, Durametallic, Five Star Seal, Jeumont-Schneider, and Interseal. EPD Services includes provision of engineered aftermarket services through its global network of 128 QRCs, some of which are co-located in manufacturing facilities, in 41 countries. Its EPD service personnel provide a comprehensive set of equipment services for flow management control systems, including installation, commissioning, repair, advanced diagnostics, re-rate and retrofit programs, machining and comprehensive asset management solutions. The Company provides asset management services and condition monitoring for rotating equipment through special contracts with many of its customers that reduce maintenance costs.

Industrial Product Division

The Company designs , manufactures, distributes and services pre-configured engineered pumps and pumps systems, including submersible motors, for industrial markets. IPD's standardized, general purpose pump products are primarily utilized by the oil and gas, chemical, water management, power generation and general industries. The Company's products are manufactured in 12 manufacturing facilities, three of which are located in the United States and six in Europe. IPD operates 20 QRCs worldwide, including 11 sites in Europe, three in the United States , five in Asia Pacific and one in Latin America. The Company manufactures approximately 40 different active types of pumps available in a wide range of metal alloys and non-metallics with a variety of configurations. The products includes Overhung, which includes Chemical Process ANSI and ISO, Industrial Process , and Slurry and Solids Handling ; Specialty Products, which includes Molten Salt VTP Pump, Submersible Pump, Thruster, Geothermal Deepwell, and Barge Pump; Between Bearings, which includes Single Case- Axially Split and Single Case- Radia! lly Split! ; Vertical, which includes Wet Pit, Deep Well Submersible Motor, Slurry and Solids Handling, and Sump; Positive Displacement, which includes Gear. The Company�� brands include Aldrich, Durco, IDP, Pacific, Pleuger, Scienco, Sier Bath, Western Land Roller, TKL, Worthington, and Worthington-Simpson. The Company markets its pump products through its worldwide sales force and its regional service and repair centers or through independent distributors and sales representatives. The Company provide an array of aftermarket services including product installation and commissioning services, spare parts, repairs, re-rate and upgrade solutions, advanced diagnostics and maintenance solutions through its global network of QRCs.

Flow Control Division

The Company�� FCD designs, manufactures, distributes and services a portfolio of industrial valve and automation solutions, including isolation and control valves, actuation, controls and related equipment. In addition, FCD offers energy management products, such as steam traps, boiler controls and condensate and energy recovery systems. FCD products are used to control, direct and manage the flow of liquids and gases and are an integral part of any flow control system. The Company's valve products are often customized and engineered to perform specific functions within each customer's unique flow control environment. The Company's flow control products are primarily used by companies operating in the chemical (including pharmaceutical), power generation (nuclear, fossil and renewable), oil and gas, water management and general industries (including aerospace, pulp and paper and mining). FCD has 58 sites worldwide, including 25 principal manufacturing facilities ( five of which are located in the United States and 13 of which are located in Europe) and 33 QRCs, including three consolidated joint ventures. A small portion of the Company's valves are also produced through an unconsolidated joint venture in India.

The Company's pr! oducts ar! e used in a variety of applications, from general service to the severe and demanding services, including those involving high levels of corrosion, extreme temperatures and/or pressures, zero fugitive emissions and emergency shutdown. The Company's smart valve and diagnostic technologies integrate sensors, microprocessor controls and software into high performance integrated control valves, digital positioners and switchboxes for automated on/off valve assemblies and electric actuators. These technologies permit real-time system analysis, system warnings and remote indication of asset health. These technologies have been developed in response to the growing demand for reduced maintenance, improved process control efficiency and digital communications at the plant level. The Company's valve automation products encompass a range of pneumatic, electric, hydraulic and stored energy actuation designs to take advantage of whatever power source the customer has available.

The Company�� products includes valve automation systems, control valves, ball valves, gate valves, globe valves, check valves, lined plug valves, lubricated plug valves, diagnostic software, digital positioners, pneumatic positioners, intelligent positioners, pneumatic actuators, hydraulic actuators, diaphragm actuators, direct gas and gas-over-oil actuators. steam traps, boiler controls, digital communications, and valve and automation repair services. The Company�� brands include Accord, Anchor/Darling, Argus, Atomac, Durco, Edward, Flowserve, Gestra, Kammer, Limitorque, McCANNA/MARPAC, NAF, NAVAL, Noble Alloy, Norbro, Nordstrom, PMV, Serck Audco, Schmidt Armaturen, Valbart, Valtek, Vogt, and Worcester Controls. The Company provides equipment maintenance services for flow control systems, including advanced diagnostics, repair, installation, commissioning, retrofit programs and field machining capabilities.

The Company competes with Sulzer Pumps, Ebara Corp., SPX Corp., Eagle Burgmann, A. W. Chesterton Co. an! d AES Cor! p, John Crane Inc., and Weir Group Plc, ITT Industries, KSB Inc., Sulzer Pumps, Pentair Ltd., Cameron International Corp., Emerson Electric Co., General Electric Co. and Crane Co.

Advisors' Opinion:

• [By Ben Levisohn]

  Xylem’s big day has also boosted other water-infrastructure stocks. Flowserve (FLS) has gained 1.2% to $70.59, Idex Corp. (IEX) has risen 0.5% to $68.69 and Thermo Fisher Scientific (TMO) has advanced 0.4% t0 $98.22.

• [By Holly LaFon]

  Flowserve Corp. (1.1%) (FLS)($70.52 - NYSE) is one of the largest global pump companies, serving the petroleum, chemical, and power industries. The company�� products include engineered and industrial pumps, automated and control valves, actuators, and seals. About 40% of FLS revenues are derived from the oil and gas industry, and should benefit from the refurbishment of the aging refineries in developed countries and the first time build out of the infrastructure in developing nations around the world. Further, oil companies are bringing up dirtier, heavier, and harder to access crude from thousands of feet below ground, as the cleaner, lighter, and easier to obtain crude that is closer to the surface is depleted. This demands more highly engineered pumps, valves, and seals that can work under very high pressure, high temperature, or underwater, boding well for FLS products.

• [By John Udovich]

  Mid cap oil services stocks Dresser-Rand Group Inc (NYSE: DRC) and�Flowserve Corp (NYSE: FLS) and small cap Propell Technologies Group Inc (OTCBB: PROP) are all direct or indirect players in the enhanced oil recovery (EOR) sector among other niches. Of course, it might seem strange to be talking about oil services or enhanced oil recovery stocks when the bottom has fallen out from under the price of oil but consider the following two charts from WTRG Economics�and Gasbuddy.com:

10 Best Machinery Stocks To Invest In Right Now: Actuant Corp (ATU)

Actuant Corporation, incorporated on October 26, 1910, is a global diversified company that designs, manufactures and distributes a range of industrial products and systems to various end markets. The Company operates four business segments: Industrial, Energy, Electrical and Engineered Solutions. The Industrial segment is primarily involved in the design, manufacture and distribution of branded hydraulic and mechanical tools to the maintenance, industrial, infrastructure and production automation markets. The Energy segment provides joint integrity products and services, as well as rope and cable solutions to the global oil and gas, power generation and other energy markets. The Electrical segment is primarily involved in the design, manufacture and distribution of a range of electrical products to the retail DIY, wholesale, original equipment manufacturer (OEM), solar, utility, marine and other harsh environment markets. The Engineered Solutions segment provides engineered position and motion control systems to OEMs in various on and off-highway vehicle markets, as well as, a range of other products to the industrial and agricultural markets. In August 2013, the Company announced the completion of its acquisition of Viking SeaTech (Viking).

Industrial

The Industrial segment is a global supplier of branded hydraulic and mechanical tools to a broad array of end markets, including general maintenance and repair, industrial, infrastructure and production automation. The Company's primary products include hydraulic tools, engineered heavy lifting solutions, workholding (production automation) solutions and concrete stressing products. These hydraulic and mechanical tools are marketed primarily through the Company's Enerpac, Simplex, Precision Sure-Lock and Milwaukee Cylinder brand names. The high-force hydraulic and mechanical tools, including cylinders, pumps, valves, specialty tools and presses.

The Company's hydraulic tools operate at high pressures of approxim! ately 5,000 to 12,000 pounds per square inch and are generally sold by a diverse group of industrial and specialty fluid power distributors to customers in the infrastructure, mining, steel mill, cement, rail, oil and gas and general maintenance industries. Key industrial distributors include W.W. Grainger, Applied Industrial Technologies and MSC. In addition to providing a line of industrial tools, the segment also provides hydraulic systems (integrated solutions) to meet customer specific requirements for safe and precise control of movement and positioning. These customized heavy lifting solutions, which combine hydraulics, steel fabrication and electronic controls with engineering and application knowledge, are typically utilized in major infrastructure projects (bridges, stadiums, tunnels and offshore platforms) for heavy lifting, launching & skidding or synchronous lifting applications.

The Industrial segment has leveraged production and engineering capabilities to also offer a range of workholding products (work supports, swing cylinders and system components) that are marketed through distributors to the automotive, machine tool and fixture design markets. In addition, the segment designs, manufactures and distributes concrete pre- and post-tensioning products (chucks and wedges, stressing jacks and anchors) which are used by concrete tensioning system designers, fabricators and installers for the residential and commercial construction, railroad, bridge, infrastructure and mining markets.

Energy

The Energy segment provides technical products and services to the global energy markets, where safety, security, reliability and productivity are key value drivers. Products include joint integrity tools and connectors for oil & gas and power generation installations, as well as rope and cable solutions. In addition to these products, the Energy segment also provides manpower services, including machining, engineering and maintenance activities. The products and ! services ! of the Energy segment are distributed and marketed under various brand names (principally Hydratight, D.L. Ricci, Morgrip, Cortland, FibronBX, Puget Sound Rope, Biach, Selantic and Jeyco) to OEMs, maintenance and service organizations and energy producers in emerging and developed countries.

Joint integrity products include hydraulic torque wrenches, bolt tensioners and portable machining equipment. These products are used in the maintenance of bolted joints on oil rigs and platforms, wind turbines, refineries and pipelines, petrochemical installations, as well as fossil fuel and nuclear power plants. The Energy segment also provides rope and cable solutions that maximize performance, safety and efficiency for customers in various markets, including oil and gas, heavy marine, subsea, ROV and seismic. With its global design and manufacturing capabilities the Cortland business is able to provide customized synthetic ropes, heavy lift slings, specialized mooring, rigging and towing systems, electro-optical-mechanical cables and umbilicals to customers, including firms, such as CGG Veritas, Expro and Sercel. These products are utilized in critical applications, often deployed in harsh operating conditions (sub-sea oil & gas production, maintenance and exploration) and are required to meet robust safety standards. In addition custom designed products are also sold into a range of other niche markets including medical, security, aerospace and defense.

Electrical

The Electrical segment is involved in the design, manufacture and distribution of a broad range of electrical products to the retail DIY, OEM, electrical distribution, power transformation and harsh environment electrical markets. The Electrical segment sells its products through a combination of distributors, direct sales personnel and manufacturers' representatives. The Electrical segment provides the retail DIY market with a range of electrical tools and consumables, such as wire strippers, electrical meters,! connecto! rs, terminals, cable ties, staples and other wire management products and conduit bending equipment under the Gardner Bender, Del City and A.W. Sperry brands. These products are sold to retailers, such as Lowe's, The Home Depot, Menards, True Value and Ace Hardware, as well as numerous electrical distributors and OEM's.

The Electrical segment sells power transformation products in North America, including low voltage, single-phase dry type transformers and custom toroidal transformers under the Acme Electric brand name and high voltage switches under the Turner Electric brand name. These transformers are sold through electrical wholesale distributors, as well as directly to OEMs, such as Rockwell Automation, Eaton, Yaskawa and General Electric. Product offerings also include electrical components and systems for the harsh environment and marine markets under the Ancor, Marinco, Guest, Mastervolt and B.E.P Marine brand names. These products are primarily sold to various customers in the industrial, marine, power generation, industrial and retail markets, including West Marine, Applied Materials and Kohler. Solar products (primarily high efficiency solar inverters for residential and small commercial applications) are sold through local distributors and installers.

Engineered Solutions

The Engineered Solutions segment is a global designer and assembler of customized position and motion control systems and other industrial products to various transportation and other niche markets. This segment focuses on providing technical and engineered products, including actuation systems, mechanical power transmission products, engine air flow management solutions and rugged electronic instrumentation. Products in the Engineered Solutions segment are primarily marketed directly to OEMs through a technical sales organization. Approximately 55% of this segment's revenue comes from the vehicle systems product line (Power-Packer, Gits and Power Gear brands), which is sold to the t! ruck, aut! omotive, off-highway and specialty vehicle markets. Products include hydraulic cab-tilt and latching systems, which are sold to global heavy duty truck OEMs, such as Volvo, Iveco, Scania, Paccar-DAF and CNHTC and electro-hydraulic convertible top latching and actuation systems. The automotive convertible top actuation systems are utilized on both retractable soft and hard top vehicles manufactured by OEMs, such as Daimler, Volkswagen, Renault, Peugeot, BMW, Volvo and Nissan.

The Company's diesel engine air flow solutions, such as exhaust gas recirculation (EGR) systems, are used by diesel engine and turbocharger manufacturers to reduce emissions, improve fuel efficiency and horsepower. Primary end markets include heavy duty truck and off-highway equipment serving customers, such as Caterpillar, Cummins, Honeywell and Borg Warner. It also sells actuation systems to various specialty vehicle OEMs (principally in the defense, recreational vehicle and off-highway markets), such as Oshkosh and Fleetwood.

The Maxima Technologies tuck-in acquisitions of Turotest Medidores Ltda and CrossControl AB, along with the fiscal 2011 acquisition of Weasler Engineering have further diversified the geographic presence, technologies and end markets of the Engineered Solutions segment. The range of products, technologies and engineered solutions of Weasler Engineering, Maxima Technologies, Elliott Manufacturing, Sanlo and Nielsen Sessions comprise the other product line within the segment. Products include severe-duty electronic instrumentation (including displays and clusters, machine controls and sensors), power transmission products (engineered power transmission components, including drive shafts, torque limiters, gearboxes, torsional dampers and flexible shafts), and a comprehensive line of case, container and industrial hardware. These products are sold to a range of niche markets, including agricultural implement, lawn & turf, construction, forestry, industrial, aerospace, material handling! and secu! rity.

Advisors' Opinion:

• [By Rich Duprey]

  Choosing to focus instead on its industrial, energy, and engineered solutions segments, diversified industrial specialist Actuant (NYSE: ATU  ) is jettisoning its electrical division, a move it expects to be completed in fiscal year 2014.

10 Best Machinery Stocks To Invest In Right Now: CNH Industrial NV (CNHI)

CNH Industrial NV is a Netherlands-based company primarily engaged in the manufacture of heavy machinery and vehicles equipment. It divides its activities into four main businesses. The Agricultural Equipment offers agricultural equipment under the New Holland Agriculture, Case IH brands and the Steyr brand. The Construction Equipment produces excavators, bulldozers, backhoes, compactors and other construction equipment under the New Holland Construction and Case Construction Equipment brands. The Trucks & Commercial Vehicles manufactures trucks and a commercial vehicles, including buses, coaches and special vehicles under Iveco, Iveco Bus and Heuliez Bus brands, as well as it produces quarry and mining equipment through Iveco Astra, and fire fighting vehicles through the Iveco Magirus brand. The Powertrain offers transmission systems, engines for marine application and power generation through FPT Industrial brand. Advisors' Opinion:

• [By Holly LaFon]

  The largest detractor for the quarter was CNH Industrial (CNHI), a global agricultural and construction equipment manufacturer, which fell 11%.� CNH released its nine-month results, which showed revenue growth of 0.6%, but the company�� margins were adversely affected by Iveco, its trucks and commercial vehicles segment.� Iveco�� margins fell short of expectations due to tough pricing, high launch costs, negative mix and increases in bad debt provisions.� Management maintains full-year guidance of 3-4% revenue growth.� We believe improvements in the Iveco division will help CNH Industrial achieve its long-term margin targets.�

10 Best Machinery Stocks To Invest In Right Now: Robogroup TEK Ltd (ROBO)

RoboGroup T.E.K Ltd. is a global, diversified enterprise with proprietary technologies on the forefront of robotics, motion control and technology education. RoboGroup's activities are organized in two related business operations: Yaskawa Eshed Technology (YET) and Intelitek.

YET, a joint venture with Japan's Yaskawa Electric Corp., which provides industrial motion controls, particularly those based on its algorithms. Intelitek, which develops, manufactures and markets training products and e-learning systems. Intelitek�� broad educational product line covers subjects such as computer-aided design, computer-aided manufacturing, configurable network computing, robotics, machine vision, hydraulics, pneumatics, sensors, process control and data acquisition. Intelitek also designs and produces integrated and customized manufacturing workcells, ranging from small-scale flexible manufacturing systems to complete computer integrated manufacturing systems.

Advisors' Opinion:

• [By Matt Krantz]

  Another way for investors to play the robotics industry is a new exchange traded fund, Robo-Stox Robotics & Automation (symbol: ROBO). The ETF owns a basket of robotics and automation stocks. One major caution, though, is that not all the stocks in the ETF are those investors traditionally think of when it comes to robotics. The largest weighting is in 3D Systems, a maker of a 3D printer, and Faro Technologies, which makes measurement devices. But none of the stocks in the ETF account for more than 4% of the total value, so the diversification helps give investors a way to play the speculative industry.

• [By John Udovich]

  Spruce Point Capital Management, LLC has released a research report about small cap robotics stock iRobot Corporation (NASDAQ: IRBT) entitled ��bout to Short Circuit,��meaning investors should take a closer look at the report, the�stock�and the performance of�robotics peer Adept Technology Inc (NASDAQ: ADEP) and�the Robo-Stox Global Robotics & Automation ETF (NASDAQ: ROBO). I should mention that we used to have both Adept Technology and iRobot Corporation in our SmallCap Network Elite Opportunity (SCN EO) portfolio�because we see the�robotics subsector improving as companies aim to reduce overhead and improve efficiencies through machine to machine (M2M) automation.